Sumain Faisal

Analyst Surprised By Exelixis Q2 Revenue Miss, Delays STELLAR-304 Readout, Halts STELLAR-305 Phase 3 Plans

Exelixis Q2 revenue missed estimates, but strong Cabometyx sales lifted earnings. STELLAR trial delays and strategy shifts shaped the update. Latest Ratings for EXEL Date Firm Action From To Feb 2022 HC Wainwright & Co. Maintains Buy Nov 2021 RBC Capital Maintains Outperform Nov 2021 HC Wainwright & Co. Maintains Buy View More Analyst Ratings…

Read More